Abstract
Pre-eclampsia is a common, pregnancy-induced disorder, consisting of hypertension and proteinuria. The condition is one of the leading causes for maternal and perinatal morbidity and mortality. Nonetheless, the underlying molecular mechanisms remain unclear. Immunological mechanisms and the renin–angiotensin system have been implicated in the development of pre-eclampsia. Agonistic autoantibodies to the angiotensin II type I receptor (AT1-AA) have been identified in pre-eclamptic patients, unifying the two hypothesis. Evidence has also accumulated for the existence and importance of a local, utroplacental renin–angiotensin system. We summarize recent data emphasizing the pathophysiological role for the autoantibodies and the uteroplacental renin–angiotensin system.
Similar content being viewed by others
References
Roberts JM, Pearson G, Cutler J, Lindheimer M (2003) Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension 41:437–445
Redman CW, Sargent IL (2005) Latest advances in understanding preeclampsia. Science 308:1592–1594
Sibai B, Dekker G, Kupferminc M (2005) Pre-eclampsia. Lancet 365:785–799
Dekker GA, Sibai BM (1998) Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 179:1359–1375
Pijnenborg R, Aplin JD, Ain R, Bevilacqua E, Bulmer JN, Cartwright J, Huppertz B, Knofler M, Maxwell C, Vercruysse L (2004) Trophoblast and the endometrium—a workshop report. Placenta 25(Suppl A):S42–S44
Roberts JM, Gammill HS (2005) Preeclampsia: recent insights. Hypertension 46:1243–1249
Redman CW, Sacks GP, Sargent IL (1999) Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 180:499–506
Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683
Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649–658
Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12:642–649
Dekker GA, Sibai BM (1999) The immunology of preeclampsia. Semin Perinatol 23:24–33
Li C, Ansari R, Yu Z, Shah D (2000) Definitive molecular evidence of renin–angiotensin system in human uterine decidual cells. Hypertension 36:159–164
Shah DM (2006) The role of RAS in the pathogenesis of preeclampsia. Curr Hypertens Rep 8:144–152
Valdes G, Germain AM, Corthorn J, Berrios C, Foradori AC, Ferrario CM, Brosnihan KB (2001) Urinary vasodilator and vasoconstrictor angiotensins during menstrual cycle, pregnancy, and lactation. Endocrine 16:117–122
Schobel HP, Fischer T, Heuszer K, Geiger H, Schmieder RE (1996) Preeclampsia—a state of sympathetic overactivity. N Engl J Med 335:1480–1485
Shah DM, Banu JM, Chirgwin JM, Tekmal RR (2000) Reproductive tissue renin gene expression in preeclampsia. Hypertens Pregnancy 19:341–351
Ward K, Hata A, Jeunemaitre X, Helin C, Nelson L, Namikawa C, Farrington PF, Ogasawara M, Suzumori K, Tomoda S et al (1993) A molecular variant of angiotensinogen associated with preeclampsia. Nat Genet 4:59–61
Morgan T, Craven C, Nelson L, Lalouel JM, Ward K (1997) Angiotensinogen T235 expression is elevated in decidual spiral arteries. J Clin Invest 100:1406–1415
Herse F, Dechend R, Harsem NK, Wallukat G, Janke J, Qadri F, Hering L, Muller DN, Luft FC, Staff AC (2007) Dysregulation of the circulating and tissue-based renin–angiotensin system in preeclampsia. Hypertension 49:604–611
Anton L, Merrill DC, Neves LA, Stovall K, Gallagher PE, Diz DI, Moorefield C, Gruver C, Ferrario CM, Brosnihan KB (2008) Activation of Local Chorionic Villi Angiotensin II Levels But Not Angiotensin (1–7) in Preeclampsia. Hypertension 51(4):1066–1072 (April)
Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC (1999) Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 103:945–952
Dechend R, Homuth V, Wallukat G, Kreuzer J, Park JK, Theuer J, Juepner A, Gulba DC, Mackman N, Haller H, Luft FC (2000) AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 101:2382–2387
Dechend R, Viedt C, Muller DN, Ugele B, Brandes RP, Wallukat G, Park JK, Janke J, Barta P, Theuer J, Fiebeler A, Homuth V, Dietz R, Haller H, Kreuzer J, Luft FC (2003) AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 107:1632–1639
Thway TM, Shlykov SG, Day MC, Sanborn BM, Gilstrap LC 3rd, Xia Y, Kellems RE (2004) Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation 110:1612–1619
Xia Y, Wen H, Bobst S, Day MC, Kellems RE (2003) Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig 10:82–93
Raijmakers MT, Dechend R, Poston L (2004) Oxidative stress and preeclampsia: rationale for antioxidant clinical trials. Hypertension 44:374–380
Lindheimer MD, Umans JG (2006) Explaining and predicting preeclampsia. N Engl J Med 355:1056–1058
Mackman N (2004) Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 24:1015–1022
Xia Y, Ramin SM, Kellems RE (2007) Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension 50:269–275
Zhou CC, Ahmad S, Mi T, Xia L, Abbasi S, Hewett PW, Sun C, Ahmed A, Kellems RE, Xia Y (2007) Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res 100:88–95
Hubel CA, Wallukat G, Wolf M, Herse F, Rajakumar A, Roberts JM, Markovic N, Thadhani R, Luft FC, Dechend R (2007) Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension 49:612–617
Stepan H, Faber R, Wessel N, Wallukat G, Schultheiss HP, Walther T (2006) Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J Clin Endocrinol Metab 91:2424–2427
Bohlender J, Ganten D, Luft FC (2000) Rats transgenic for human renin and human angiotensinogen as a model for gestational hypertension. J Am Soc Nephrol 11:2056–2061
Takimoto E, Ishida J, Sugiyama F, Horiguchi H, Murakami K, Fukamizu A (1996) Hypertension induced in pregnant mice by placental renin and maternal angiotensinogen. Science 274:995–998
Dechend R, Gratze P, Wallukat G, Shagdarsuren E, Plehm R, Brasen JH, Fiebeler A, Schneider W, Caluwaerts S, Vercruysse L, Pijnenborg R, Luft FC, Muller DN (2005) Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension 45:742–746
Dechend R, Llinas M, Caluwaerts S, Herse F, Lamarca B, Mueller DN, Luft FC, Pijnenborg R, Wallukat G, Granger JP (2006) Agonistic autoantibodies to the AT1 receptor in rat models of preeclampsia: induced by chronic reduction in uterine perfusion pressure (RUPP) and low dose TNF-a infusion [abstract]. Hypertens Pregnancy 25:70
Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA (2001) Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension 38:718–722
Faas MM, Schuiling GA, Baller JF, Visscher CA, Bakker WW (1994) A new animal model for human preeclampsia: ultra-low-dose endotoxin infusion in pregnant rats. Am J Obstet Gynecol 171:158–164
Walther T, Wallukat G, Jank A, Bartel S, Schultheiss HP, Faber R, Stepan H (2005) Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension 46:1275–1279
Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schonemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G (2005) Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352:558–569
Fu ML, Herlitz H, Schulze W, Wallukat G, Micke P, Eftekhari P, Sjogren KG, Hjalmarson A, Muller-Esterl W, Hoebeke J (2000) Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens 18:945–953
Ingelfinger JR (2005) Agonistic autoantibodies and rejection of renal allografts. N Engl J Med 352:617–619
Kamijo K, Ishikawa K, Tanaka M (2005) Clinical evaluation of 3rd generation assay for thyrotropin receptor antibodies: the M22-biotin-based ELISA initiated by Smith. Endocr J 52:525–529
Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, Lohse MJ (2004) Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 113:1419–1429
AbdAlla S, Lother H, el Massiery A, Quitterer U (2001) Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 7:1003–1009
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Herse, F., Staff, A.C., Hering, L. et al. AT1-receptor autoantibodies and uteroplacental RAS in pregnancy and pre-eclampsia. J Mol Med 86, 697–703 (2008). https://doi.org/10.1007/s00109-008-0332-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-008-0332-4